All In Biotech

Drug Trial Radar · NCT07942285

Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5

Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Patients With PD-L1 CPS <5 Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Controlled, Multicenter, Phase III Clinical Study

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 525 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

525

Planned (sponsor's estimate)

Start

Nov 20, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Tianjin Medical University Cancer Institute and Hospital; West China Hospital
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, controlled Phase III clinical study designed to evaluate the efficacy and safety of sintilimab plus ipilimumab N01 and chemotherapy compared with sintilimab plus chemotherapy as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of less than 5. Eligible patients will be randomly assigned to receive either sintilimab plus ipilimumab N01 and chemotherapy or sintilimab plus chemotherapy. The study aims to determine whether the addition of ipilimumab N01 to sintilimab plus chemotherapy can improve clinical outcomes in this patient population while evaluating the safety of the combination regimen.

Conditions

  • Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Interventions

  • sintilimab+IBI310+chemotherapyDrug

    Patients in the experimental arm will receive a single dose of ipilimumab N01 (3 mg/kg IV), combined with sintilimab (200 mg IV, Q3W) and XELOX or SOX chemotherapy for 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1. Subsequent dosing of ipilimumab N01 will be determined based on radiological assessments per RECIST v1.1 and safety evaluations.

  • sintilimab+chemotherapyDrug

    Patients in the active comparator arm will receive sintilimab (200 mg IV, Q3W) plus XELOX or SOX chemotherapy for up to 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization to death from any cause, assessed up to 48 months.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, Jiangsu, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.